Precision BioSciences (NASDAQ:DTIL) Director Geno Germano Buys 2,609 Shares of Stock

Key Points

• Director insider buying: Geno Germano purchased 2,609 Precision BioSciences shares at an average price of $6.28, increasing his position by 5.81% to 47,492 shares.
• Financial performance remains weak: Precision BioSciences reported quarterly EPS of -$1.26, missing estimates of -$0.80, alongside a negative net margin of 96.73% and negative return on equity of 72.52%.
• Analyst sentiment is mixed but broadly positive: Four analysts rate the stock Buy and one rates it Sell, resulting in a “Moderate Buy” consensus and a $32.25 average price target; institutional investors own 37.99% of the shares.

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) Director Geno Germano bought 2,609 shares of the stock in a transaction on Friday, September 25th. The stock was purchased at an average cost of $6.28 per share, for a total transaction of $16,384.52. Following the acquisition, the director directly owned 47,492 shares of the company's stock, valued at $298,249.76. The trade was a 5.81% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Precision BioSciences Trading Up 0.3%

Shares of DTIL stock opened at $6.24 on Tuesday. The stock has a market cap of $172.22 million, a P/E ratio of -2.23 and a beta of 1.24. The company has a quick ratio of 12.82, a current ratio of 12.82 and a debt-to-equity ratio of 0.50. Precision BioSciences, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $9.62. The business has a fifty day simple moving average of $7.37 and a 200-day simple moving average of $7.19.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. On average, analysts forecast that Precision BioSciences, Inc. will post -3.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Precision BioSciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Octagon Capital Advisors LP lifted its stake in shares of Precision BioSciences by 16.6% during the first quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company's stock valued at $12,302,000 after buying an additional 318,737 shares during the period. Empery Asset Management LP purchased a new stake in Precision BioSciences in the 4th quarter worth approximately $9,130,000. Affinity Asset Advisors LLC purchased a new stake in Precision BioSciences in the 1st quarter worth approximately $3,289,000. Squarepoint Ops LLC raised its holdings in Precision BioSciences by 212.7% in the 2nd quarter. Squarepoint Ops LLC now owns 137,106 shares of the company's stock valued at $1,078,000 after acquiring an additional 93,258 shares during the last quarter. Finally, Corient Private Wealth LP raised its holdings in Precision BioSciences by 70.4% in the 2nd quarter. Corient Private Wealth LP now owns 245,058 shares of the company's stock valued at $1,926,000 after acquiring an additional 101,206 shares during the last quarter. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on DTIL. HC Wainwright reiterated a "buy" rating on shares of Precision BioSciences in a research report on Monday, August 3rd. Wall Street Zen lowered Precision BioSciences from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Precision BioSciences in a report on Wednesday, August 5th. Finally, Oppenheimer began coverage on Precision BioSciences in a research report on Tuesday, June 9th. They set an "outperform" rating and a $20.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $32.25.

Precision BioSciences Company Profile

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.